Snapshot from Jul 29, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / UroGen Pharma CMO Sells Stock
Business insider stock sale

UroGen Pharma CMO Sells Stock

Analysis based on 9 articles · First reported Jun 14, 2026 · Last updated Jul 01, 2026

Sentiment
-10
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The insider stock sales by Mark Schoenberg, CMO of UroGen Pharma Ltd., could lead to a slight negative sentiment among investors, as it might be perceived as a lack of confidence, despite explanations of routine liquidity management. However, the company's positive sales growth for Jelmyto and Zusduri, along with shrinking losses, could offset some of this concern. The future generic competition from Sun Pharma for Jelmyto starting in 2030 introduces a long-term risk for UroGen Pharma Ltd.'s revenue stream.

biotechnology pharmaceuticals
Event Summary

Mark Schoenberg, the Chief Medical Officer of UroGen Pharma Ltd., conducted multiple stock sales in June 2026. On June 22, 2026, he sold 10,000 shares of common stock for approximately $350,100. Earlier, on June 8, 2026, he exercised 10,000 options and immediately sold 5,222 ordinary shares for about $143,000. These transactions reduced his direct holdings in UroGen Pharma Ltd. but he still retains a significant ownership stake. The sales are characterized as routine liquidity management. Separately, UroGen Pharma Ltd. settled with Sun Pharma, granting a non-exclusive license for a generic version of Jelmyto starting September 15, 2030. UroGen Pharma Ltd. reported strong sales growth for its products Jelmyto and Zusduri in Q1 2026, and its losses are shrinking.

Key Actions
90 Mark Schoenberg sold shares
60 UroGen Pharma settled with Sun Pharma
Entities Involved
stock
UroGen Pharma
UroGen Pharma Ltd. is the company whose stock was sold by its CMO. The company is developing and commercializing specialty therapeutics for urothelial cancers. The insider sales could be perceived negatively by investors, though the company's financial performance and pipeline show positive developments.
Importance 100.0 Sentiment -5.0
per
Mark Schoenberg
Mark Schoenberg, the Chief Medical Officer of UroGen Pharma Ltd., sold shares of the company's common stock in multiple transactions, reducing his direct holdings but still maintaining a significant ownership position. These sales are described as routine liquidity management.
Importance 80.0 Sentiment -10.0
stock
Sun Pharma
Sun Pharma, a generic drug manufacturer, settled with UroGen Pharma Ltd. to receive a non-exclusive license to sell a generic version of Jelmyto starting September 15, 2030. This will introduce future competition for UroGen Pharma Ltd.'s product.
Importance 30.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.